A detailed history of Bedel Financial Consulting, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Bedel Financial Consulting, Inc. holds 12,302 shares of ABBV stock, worth $2.1 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
12,302
Previous 12,267 0.29%
Holding current value
$2.1 Million
Previous $2.1 Million 15.45%
% of portfolio
0.34%
Previous 0.3%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$163.84 - $199.33 $5,734 - $6,976
35 Added 0.29%
12,302 $2.43 Million
Q2 2024

Aug 05, 2024

BUY
$154.79 - $180.76 $2,786 - $3,253
18 Added 0.15%
12,267 $2.1 Million
Q1 2024

May 07, 2024

SELL
$159.82 - $182.1 $10,548 - $12,018
-66 Reduced 0.54%
12,249 $2.23 Million
Q4 2023

Feb 08, 2024

SELL
$137.6 - $154.97 $43,206 - $48,660
-314 Reduced 2.49%
12,315 $1.91 Million
Q3 2023

Feb 08, 2024

BUY
$133.59 - $154.65 $12,557 - $14,537
94 Added 0.75%
12,629 $1.88 Million
Q2 2023

Aug 10, 2023

BUY
$132.51 - $164.9 $20,274 - $25,229
153 Added 1.24%
12,535 $1.69 Million
Q1 2023

May 02, 2023

SELL
$144.61 - $166.54 $15,039 - $17,320
-104 Reduced 0.83%
12,382 $1.97 Million
Q4 2022

Feb 07, 2023

BUY
$138.31 - $165.87 $40,248 - $48,268
291 Added 2.39%
12,486 $2.02 Million
Q3 2022

Nov 08, 2022

BUY
$134.21 - $153.93 $4,563 - $5,233
34 Added 0.28%
12,195 $1.81 Million
Q2 2022

Aug 04, 2022

BUY
$137.62 - $174.96 $27,111 - $34,467
197 Added 1.65%
12,161 $1.86 Million
Q1 2022

Apr 19, 2022

BUY
$131.98 - $163.75 $46,984 - $58,295
356 Added 3.07%
11,964 $1.94 Million
Q4 2021

Jan 11, 2022

BUY
$107.43 - $135.93 $53,070 - $67,149
494 Added 4.44%
11,608 $1.57 Million
Q3 2021

Oct 12, 2021

BUY
$106.4 - $120.78 $193,967 - $220,181
1,823 Added 19.62%
11,114 $1.2 Million
Q2 2021

Aug 03, 2021

BUY
$105.21 - $117.21 $57,444 - $63,996
546 Added 6.24%
9,291 $1.05 Million
Q1 2021

Apr 26, 2021

BUY
$102.3 - $112.62 $88,489 - $97,416
865 Added 10.98%
8,745 $946,000
Q4 2020

Feb 02, 2021

BUY
$80.49 - $108.67 $42,257 - $57,051
525 Added 7.14%
7,880 $844,000
Q3 2020

Oct 20, 2020

SELL
$85.91 - $100.83 $16,408 - $19,258
-191 Reduced 2.53%
7,355 $644,000
Q2 2020

Jul 14, 2020

SELL
$73.37 - $98.18 $45,416 - $60,773
-619 Reduced 7.58%
7,546 $741,000
Q1 2020

May 06, 2020

BUY
$64.5 - $97.79 $63,016 - $95,540
977 Added 13.59%
8,165 $622,000
Q4 2019

Jan 28, 2020

BUY
$72.13 - $90.25 $72 - $90
1 Added 0.01%
7,188 $636,000
Q3 2019

Oct 09, 2019

SELL
$62.98 - $75.72 $11,021 - $13,251
-175 Reduced 2.38%
7,187 $544,000
Q2 2019

Aug 01, 2019

SELL
$65.7 - $83.98 $7,095 - $9,069
-108 Reduced 1.45%
7,362 $535,000
Q1 2019

May 02, 2019

BUY
$77.14 - $90.79 $23,836 - $28,054
309 Added 4.32%
7,470 $602,000
Q4 2018

Jan 28, 2019

SELL
$77.85 - $96.01 $18,294 - $22,562
-235 Reduced 3.18%
7,161 $660,000
Q3 2018

Nov 01, 2018

BUY
$88.91 - $98.84 $19,560 - $21,744
220 Added 3.07%
7,396 $679,000
Q2 2018

Jul 18, 2018

BUY
$89.78 - $106.23 $200,658 - $237,424
2,235 Added 45.23%
7,176 $665,000
Q1 2018

May 03, 2018

SELL
$92.01 - $123.21 $10,121 - $13,553
-110 Reduced 2.18%
4,941 $468,000
Q4 2017

Feb 06, 2018

BUY
$89.56 - $98.21 $452,367 - $496,058
5,051
5,051 $488,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $301B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Bedel Financial Consulting, Inc. Portfolio

Follow Bedel Financial Consulting, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bedel Financial Consulting, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bedel Financial Consulting, Inc. with notifications on news.